<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059457</url>
  </required_header>
  <id_info>
    <org_study_id>720-OAA-18C-00083</org_study_id>
    <nct_id>NCT05059457</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Sampling Methods for Hemoglobin Measurement</brief_title>
  <official_title>A Pilot to Asses Hemoglobin Concentration Obtained From Capillary and Venous Blood Measured Using the HemoCue 201+ Hemoglobin Analyzer in a Controlled and Field Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICF Macro, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uganda Bureau of Statistics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ICF Macro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to inform The DHS Program on whether there are variations in&#xD;
      hemoglobin concentration using the DHS standard technique of a single drop of capillary blood&#xD;
      and alternative blood sources (pooled capillary and venous blood) using the HemoCue 201+&#xD;
      analyzer compared to venous blood using a clinical hematology autoanalyzer.&#xD;
&#xD;
      Research Objectives:&#xD;
&#xD;
        1. To determine if there are differences in the hemoglobin concentration between a single&#xD;
           drop of capillary blood (blood drop #3) and a pooled drop of capillary blood measured on&#xD;
           the HemoCue 201+ analyzer in apparently healthy non-pregnant women age 15-49 and&#xD;
           children age 6-59 months in a controlled setting (i.e., blood specimens are collected in&#xD;
           a laboratory setting).&#xD;
&#xD;
        2. To determine if there are differences in the hemoglobin concentration between a single&#xD;
           drop of capillary blood (blood drop #3) measured on the HemoCue 201+ analyzer against&#xD;
           venous blood measured on HemoCue 201+ analyzer and a clinical autoanalyzer in apparently&#xD;
           healthy non-pregnant women age 15-49 and children age 6-59 months in a controlled and&#xD;
           field setting.&#xD;
&#xD;
        3. To determine if there are differences in the hemoglobin concentration between a pooled&#xD;
           drop of capillary blood measured on the HemoCue 201+ analyzer against venous blood&#xD;
           measured on HemoCue 201+ analyzer and a clinical autoanalyzer in apparently healthy&#xD;
           non-pregnant women age 15-49 and children age 6-59 months in a controlled and field&#xD;
           setting.&#xD;
&#xD;
        4. To compare results of hemoglobin distribution and estimates of anemia prevalence using&#xD;
           two types of capillary blood (single drop and pooled) and venous blood measured on the&#xD;
           HemoCue 201+ analyzer and a clinical autoanalyzer using venous blood in a controlled and&#xD;
           field setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin measurement</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference (correlation, concordance, paired t-test) in hemoglobin concentration between each blood source measured with the HemoCue 201+ compared to venous blood measured with a clinical autoanalyzer.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Controlled setting: single capillary and pooled capillary and venous blood</arm_group_label>
    <description>Single drop capillary blood, pooled capillary blood, and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a controlled setting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Field setting: single capillary and venous blood</arm_group_label>
    <description>Single drop capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Field setting: pooled capillary and venous blood</arm_group_label>
    <description>Pooled capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood source: single and pooled capillary and venous blood</intervention_name>
    <description>A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.&#xD;
Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.&#xD;
Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.</description>
    <arm_group_label>Controlled setting: single capillary and pooled capillary and venous blood</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood source: single capillary and venous blood</intervention_name>
    <description>A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .&#xD;
Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.</description>
    <arm_group_label>Field setting: single capillary and venous blood</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood source: pooled capillary and venous blood</intervention_name>
    <description>Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.&#xD;
Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.</description>
    <arm_group_label>Field setting: pooled capillary and venous blood</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be children 6-59 months and non-pregnant women 15-49 years. In the&#xD;
        controlled setting, participants will be selected from nearby communities and brought to&#xD;
        the Ebenezer Lab in Kampala, Uganda. In the field setting, participants will be selected&#xD;
        from households eligible for the DHS-8 questionnaire pilot in districts located near&#xD;
        Kampala, Uganda.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 6-59 months or non-pregnant women 15-49&#xD;
&#xD;
          -  Apparently healthy individuals&#xD;
&#xD;
          -  Consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children less than 6 months or over 59 months&#xD;
&#xD;
          -  Women less than 15 years of age or greater than 49 years of age&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>49 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sorrel ML Namaste, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rhona Baingana, BSc, MSc</last_name>
    <phone>256792405152</phone>
    <email>rbaingana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ebenezer Lab</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Kiyimba-Kaggwa</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Kiyimba-Kaggwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rhona Baingana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uganda Bureau of Statistics</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kakande</last_name>
    </contact>
    <investigator>
      <last_name>Pamela Kakande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>DHS surveys</keyword>
  <keyword>Point-of-care</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Survey methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

